Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724-5081, USA.
Oral Oncol. 2011 May;47(5):414-9. doi: 10.1016/j.oraloncology.2011.03.011. Epub 2011 Apr 7.
We would like to evaluate the effectiveness of Tomotherapy for decreasing radiation dose to the cochlea in head and neck cancer patients. A retrospective review of 72 patients undergoing radiation for head and neck cancer was performed. Cochlea dose was compared between 20 patients treated with conventional intensity modulated radiotherapy (IMRT) and 52 treated with Tomotherapy. A review of literature was performed to assess cochlea dose reported with the IMRT technique for head and neck cancer. Mean total cochlea dose was 36 Gy for IMRT compared to 12.1 Gy for Tomotherapy (p=0.002). Mean right cochlea dose was respectively, 16.6 and 6.2 Gy for IMRT and Tomotherapy (p=0.007), and 19.3 and 5.9 Gy for the left. Cochlea (p=0.002). Mean cochlea dose reported in the literature ranged from 16 to 55 Gy with IMRT for head and neck cancer. Helical Tomotherapy for head and neck cancer may significantly decrease radiation dose to the cochlea without sacrificing target volume coverage.
我们希望评估螺旋断层放疗（Tomotherapy）降低头颈部癌症患者耳蜗剂量的效果。对 72 例接受头颈部癌症放疗的患者进行了回顾性研究。比较了 20 例接受常规调强放疗（IMRT）和 52 例接受 Tomotherapy 治疗的患者的耳蜗剂量。对 IMRT 技术治疗头颈部癌症时报道的耳蜗剂量进行了文献复习。IMRT 的平均总耳蜗剂量为 36Gy，而 Tomotherapy 为 12.1Gy（p=0.002）。IMRT 和 Tomotherapy 的右耳蜗平均剂量分别为 16.6Gy 和 6.2Gy（p=0.007），左耳蜗平均剂量分别为 19.3Gy 和 5.9Gy（p=0.002）。文献报道的 IMRT 治疗头颈部癌症的平均耳蜗剂量范围为 16 至 55Gy。螺旋断层放疗治疗头颈部癌症可能会显著降低耳蜗剂量，同时不牺牲靶区覆盖。
